Press release

Financial Statement 1 January - 31 December 2009

- After the end of the reporting period BioInvent announced a directed issue of new shares amounting to SEK 150 million.

- At the year end the first patient was treated in a phase I study of the BI-505 product candidate for the treatment of multiple myeloma.

- In the Phase II study of the product candidate TB-402 for the prevention of thrombosis, all the patients had been treated by the end of October 2009.

- The phase I study of TB-403 in patients with advanced cancer was successfully completed in November 2009. The product candidate was shown to be well tolerated.

- Technology transfer under the terms of the alliance with Roche on product candidate TB-403 triggered during the first quarter 2009 a success fee of EUR 5 million to BioInvent and ThromboGenics.

- The phase I trial of BI-204 was completed in the second quarter 2009. The product candidate for the prevention of secondary events in patients with cardiovascular disease was well tolerated. The drug is being co-developed with Genentech, a wholly-owned member of the Roche Group.

- During the third and fourth quarters of 2009 agreements were signed with Mitsubishi Tanabe Pharma Corp. and Daichi Sankyo respectively for research and development of antibody-based drugs.

- In November 2009 BioInvent won the "Licensing Deal of the Year" award at the Scrip Awards 2009.

- Net revenues for January - December 2009: SEK 80.7 million (252.1 including initial milestone payment of 187.6 relating to TB-403).

- Current investments together with cash and bank as of 31 December 2009: SEK 84.0 million (212.5).

- Cash flow from current operations and investment activities for January - December 2009: SEK -128.4 million (-4.4).

- Loss after tax for January - December 2009 amounted to SEK -176.7 million (16.2) and the profit after tax per share was SEK -3.17 (0.29).

Contact
Any questions regarding this report will be answered by:

BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.

College Hill
Justine Lamond, Sue Charles and Benjamyn Tan, tel. +44 (0)20 7457 2020, [email protected]

The report is also available at www.bioinvent.com